IL-23 promotes tumour incidence and growth
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Chronic inflammation has long been associated with increased incidence of malignancy and similarities in the regulatory mechanisms have been suggested for more than a century. Infiltration of innate immune cells, elevated activities of matrix metalloproteases and increased angiogenesis and vasculature density are a few examples of the similarities between chronic and tumour-associated inflammation. Conversely, the elimination of early malignant lesions by immune surveillance, which relies on the cytotoxic activity of tumour-infiltrating T cells or intra-epithelial lymphocytes, is thought to be rate-limiting for the risk to develop cancer. Here we show a molecular connection between the rise in tumour-associated inflammation and a lack of tumour immune surveillance. Expression of the heterodimeric cytokine interleukin (IL)-23, but not of its close relative IL-12, is increased in human tumours. Expression of these cytokines antagonistically regulates local inflammatory responses in the tumour microenvironment and infiltration of intra-epithelial lymphocytes. Whereas IL-12 promotes infiltration of cytotoxic T cells, IL-23 promotes inflammatory responses such as upregulation of the matrix metalloprotease MMP9, and increases angiogenesis but reduces CD8 T-cell infiltration. Genetic deletion or antibody-mediated elimination of IL-23 leads to increased infiltration of cytotoxic T cells into the transformed tissue, rendering a protective effect against chemically induced carcinogenesis. Finally, transplanted tumours are growth-restricted in hosts depleted for IL-23 or in IL-23-receptor-deficient mice. Although many strategies for immune therapy of cancer attempt to stimulate an immune response against solid tumours, infiltration of effector cells into the tumour tissue often appears to be a critical hurdle. We show that IL-23 is an important molecular link between tumour-promoting pro-inflammatory processes and the failure of the adaptive immune surveillance to infiltrate tumours.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IL-17 also induces proliferative signaling in keratinocytes through Act1, a major facet of its impact in psoriasis and perhaps also explaining its involvement in skin tumorigenesis”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
In the citing paper
“this pro-proliferative role likely contributes to the pathogenic effects of IL-17 in psoriasis, as well as potentially in skin cancer”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
In the citing paper
“In addition, as discussed above, IL-17 promotes proliferation of skin epithelial cells to promote tumorigenesis”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Self-citationInterleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1001 · Cited by 3,927
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906
Self-citationOppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00070-4 · Cited by 2,822
Self-citationMatrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Cited by
Items 601–700 of 1,000
Chapman, P. B. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.09.013 · Cited by 20
IL-23 Inhibits Melanoma Development by Augmenting DNA Repair and Modulating T Cell Subpopulations
Nasti, T. H., Cochran, J. B., Vachhani, R. V., McKay, K., Tsuruta, Y., Athar, M., Timares, L., & Elmets, C. A. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601455 · Cited by 19
“However, rather than the complete inhibition of epithelial tumors reported for IL-12/IL-23p40KO in C57BL/6 mice (23), deficiency of both cytokines in C3H/HeN mice resulted in an intermediate number of epithelial tumors.”
BackgroundResultInfluentialImmuno-oncology-microbiome axis of gastrointestinal malignancy
Lin, Q., Guan, S.-W., & Yu, H. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i5.757 · Cited by 28
Nouri, N., Maleki, L. A., Soltani‐Zangbar, M. S., Kamrani, A., Mehdizadeh, A., Danaii, S., Heris, J. A., Chakari-Khiavi, F., & Yousefi, M. (2024) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2024.104290 · Cited by 19
Seliger, B., & Massa, C. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00419 · Cited by 22
“While it represent a component of the “gold standard” cocktail for vaccine DC maturation (61) due to its role in promoting CCR7-mediated migration (62), and it also induces the expression of costimulatory molecules like OX40-L and CD70 promoting T cell functions (63, 64), it can inhibit the synthesis of IL-12p70 (65),…”
BackgroundYu, J. Q., Zeng, Z., Wang, S., Tian, L., Wu, J., Xue, L., Lee, C. W., Zhang, M.-D., Goggins, W. B., Chen, M., et al. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.644 · Cited by 19
“However, IL-23 gene was reported to promote gastric cancer incidence and growth in gene knock-out model [18], which is in the same trend with our study.”
ResultCutaneous Manifestations of Reactions to Biologics
Otani, I. M., Levin, A. S., & Banerji, A. (2018) · Current Allergy and Asthma Reports · doi:10.1007/s11882-018-0764-z · Cited by 19
The Contribution of Interleukin-12 Genetic Variations to Taiwanese Lung Cancer
Wu, M.-F., WANG, Y.-C., Li, H.-T., Chen, W., Liao, C.-H., Shih, T., CHANG, W.-S., Tsai, C.-W., Hsia, T., & BAU, D.-T. (2018) · Anticancer Research · doi:10.21873/anticanres.12989 · Cited by 20
Argemí, J., Ponz‐Sarvisé, M., & Sangro, B. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2022.03.002 · Cited by 22
Innate lymphoid cells involve in tumorigenesis
Tian, Z., van Velkinburgh, J. C., Wu, Y., & Ni, B. (2015) · International Journal of Cancer · doi:10.1002/ijc.29443 · Cited by 20
Pathological Role of Interleukin-17 in Poly I:C-Induced Hepatitis
He, J., Lang, G., Ding, S., & Li, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073909 · Cited by 21
“Several studies have suggested pro-tumor effect of Th17 cells or IL-17A in hepatic tumor formation and progression, shortening patient survival by promoting tumor angiogenesis [34,35,36].”
BackgroundRegulation of Interleukin-23 Expression in Health and Disease
Welsby, I., & Goriely, S. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-94-024-0921-5_8 · Cited by 21
Amer, T., Elbaz, R., Mokhtar, A.-R., El-Shaer, S., Elshazli, R. M., & Settin, A. (2017) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2017.1320680 · Cited by 20
Experimental Lung Metastases in Mice Are More Effectively Inhibited by Blockade of IL23R than IL23
Yan, J., Allen, S. M., Vijayan, D., Li, X.-Y., Harjunpää, H., Takeda, K., Liu, J., Cua, D. J., Smyth, M. J., & Teng, M. W. L. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0011 · Cited by 19
“In humans, increased expression of IL23p19 subunit mRNA and serum IL23 has been reported in a number of malignancies including melanoma, colon, and lung cancers (4, 14).”
BackgroundAnti‐cytokine vaccines and the immunotherapy of autoimmune diseases
Wraith, D. C. (2006) · European Journal of Immunology · doi:10.1002/eji.200636760 · Cited by 20
“Thus, IL-12 promotes tumour infiltration by cytotoxic T cells whereas IL-23 may decrease infiltration of cytotoxic T cells while promoting angiogenesis [31] in some cancers.”
BackgroundPrevention and management of cutaneous immune‐related adverse events: EADV Task Force statement
Fattore, D., Apalla, Z., Freites‐Martínez, A., Tommasino, N., Nikolaou, V. A., Lauletta, G., Ortiz‐Brugués, A., Sollena, P., Starace, M. V. R., Gomes, N. P., et al. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.70149 · Cited by 20
“58,59 Conflicting data exist regarding the safety of anti- IL-12/23, as IL-12 plays a protective role against skin inflammation 60 and suppresses tumour growth and metastasis through IFN synthesis stimulation.”
Clinical Trials with Immunotherapy for High-Grade Glioma
Ruzevick, J., Jackson, C. M., Phallen, J. A., & Lim, M. K. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.04.003 · Cited by 19
Vangilbergen, M., Stockman, A., Velde, A. V. D., Garmyn, M., Punie, K., & Hillary, T. (2024) · JAAD International · doi:10.1016/j.jdin.2024.06.006 · Cited by 17
“14,18 In contrast to previous beliefs, an anticarcino-genic role for IL-23 and IL-17 has been described.”
BackgroundSirikanjanapong, S., Lanson, B. G., Amin, M. R., Martiniuk, F. T., Kamino, H., & Wang, B. Y. (2010) · Head and Neck Pathology · doi:10.1007/s12105-010-0200-8 · Cited by 18
“IL-23 recently has been demonstrated to be a promising cancer vaccine for melanoma [23, 24].”
BackgroundGenetic polymorphism of IL-23R influences susceptibility to HCV-related hepatocellular carcinoma
Labib, H. A., Ahmed, H. S., Shalaby, S. M., Wahab, E. A., & Hamed, E. F. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.01.012 · Cited by 18
Role of IL-12p40 in cervical carcinoma
Zijlmans, H. J. M. A. A., Punt, S., Fleuren, G. J., Trimbos, J. B., Kenter, G. G., & Gorter, A. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.488 · Cited by 19
“Our results support a previously suggested immunosuppressive role for IL-23 (Langowski et al, 2006).”
BackgroundResultAntimelanoma Immunotherapy: Clinical and Preclinical Applications of Il-12 Family Members
Nagai, H., Oniki, S., Fujiwara, S., Yoshimoto, T., & Nishigori, C. (2010) · Immunotherapy · doi:10.2217/imt.10.46 · Cited by 20
Yang, Q., El-Sayed, Y. Y., Rosenberg‐Hasson, Y., Hirschberg, D. L., Nayak, N. R., Schilling, J., & Madan, A. (2009) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2009.00743.x · Cited by 18
IL-27 suppresses SKOV3 cells proliferation by enhancing STAT3 and inhibiting the Akt signal pathway
Zhang, Z., Zhou, B., Zhang, K., Song, Y., Zhang, L., & Xi, M. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.09.014 · Cited by 18
Usó, M., Lewintre, E. J., Fariñas, S. C., Blasco, A., del Olmo, E. G., Guijarro, R., Martorell, M., Camps, C., & Sirera, R. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1260214 · Cited by 20
“can impair CD8C T-cell-mediated immune surveillance and promote tumor neovascularization.(53) But on the other hand, other groups have reported that IL23 exerts antitumor activity by stimulating T cells and natural killer (NK) cells.”
BackgroundSkin Cancer: Genetics, Immunology, Treatments, and Psychological Care
Tavakolpour, S., Daneshpazhooh, M., & Mahmoudi, H. (2017) · Springer eBooks · doi:10.1007/978-3-319-64550-6_18 · Cited by 20
Fung, K. Y., Nguyen, P. M., & Putoczki, T. L. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.11.013 · Cited by 18
High IL-12 p35 and IL-23 p19 mRNA expression is associated with superior outcome in ovarian cancer
Wolf, A. M., Rumpold, H. F., Reimer, D., Marth, C., Zeimet, A. G., & Wolf, D. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.05.024 · Cited by 18
Kiyomi, A., Makita, M., Ozeki, T., Li, N., Satomura, A., Tanaka, S., Onda, K., Sugiyama, K., Iwase, T., & Hirano, T. (2015) · Translational Oncology · doi:10.1016/j.tranon.2015.06.004 · Cited by 18
“Cancer tissues are suggested to express IL-17 [33,34], and IL-17 promotes cancer angiogenesis resulting in cancer advance [35].”
BackgroundYaghoobi, M., Gouvello, S. L., Aloulou, N., Dutreuil, C., Walker, F., & Sobhani, I. (2010) · Colorectal Disease · doi:10.1111/j.1463-1318.2010.02283.x · Cited by 18
Zanetti (2010) · Journal of Inflammation Research · doi:10.2147/jir.s11190 · Cited by 22
“The tumorigenic nature of IL-6, IL-23, and TNF-α 27–29 as well as of other molecules released by tumor cells and tumor infiltrating immune cells under ER stress, 30 makes it plausible to suggest that one of the mechanisms by which ER stress aids tumor growth is by mediating the release of”
Neutralization of IL-23 depresses experimental ocular neovascularization
Cai, Y., Tan, W., Shen, X. P., Zhu, Y., Gao, Y., Sui, A., Lü, Q., Zhong, Y., & Xie, B. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2016.02.008 · Cited by 17
Immune Cell Interplay in the Fight Against GBM
Vallieri, N., & Datsi, A. (2025) · Cancers · doi:10.3390/cancers17050817 · Cited by 17
“CTLA-4, another immune checkpoint molecule expressed on T REGs and activated T H cells, appears to be critical for immune evasion in GBM [80].”
ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression
Sheldon, H., Bridges, E., Silva, I., Masiero, M., Favara, D. M., Wang, D., Leek, R., Snell, C. E., Roxanis, I., Kreuzer, M., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0171 · Cited by 17
“This cytokine can also increase tumor-cell proliferation and inhibit antitumor immune responses by reducing CD4þ and CD8þ T cells in the tumor microenvironment as well as increasing M2-macrophage and neutrophil infiltration (21, 22).”
BackgroundCytokines and cytokine receptors
O’Shea, J. J., Tato, C. M., & Siegel, R. M. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04404-2.10010-7 · Cited by 18
Tildrakizumab for treating psoriasis
Galluzzo, M., D’Adamio, S., Bianchi, L., & Talamonti, M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1304537 · Cited by 17
El‐Gedamy, M. S., El-Khayat, Z., Abol‐Enein, H., Elsaid, A. M. M., & El-Nahrery, E. M. A. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155355 · Cited by 16
Roma, S., Carpen, L., Raveane, A., & Bertolini, F. (2021) · Cancers · doi:10.3390/cancers13205042 · Cited by 17
“In this kind of tumor and in response to IL-23, ILC3s lack NCR expression and produce IL-17, which in turn limits CD8+ T cell anti-tumor activity Cancers 2021, 13, 5042 9 of 32 and contributes to cancer progression [131] (Figure 1).”
BackgroundInfluentialCocco, C., Pistoia, V., & Airoldi, I. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.11.006 · Cited by 18
Peng, Q., QIN, Y., Chen, Z., Deng, Y., Xu, J., Li, S., & Qin, X. Y. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1558 · Cited by 16
Stanilov, N., Miteva, L. D., Dobreva, Z. G., Jovchev, J. P., Cirovski, G., & Stanilova, S. A. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-1987-z · Cited by 16
Vis, P. W. R., Bouten, C. V. C., Sluijter, J. P. G., Pasterkamp, G., van Herwerden, L. A., & Kluin, J. (2009) · Tissue Engineering Part A · doi:10.1089/ten.tea.2009.0331 · Cited by 18
Giuliani, N., & Airoldi, I. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1724 · Cited by 18
An Overview of Cytokine Regulation of Inflammation and Immunity
Meager, A., & Wadhwa, M. (2013) · Wiley eBooks · doi:10.1002/9780470015902.a0024658 · Cited by 17
Common flora and intestine: A carcinogenic marriage
Wang, K., & Karin, M. (2013) · Cellular Logistics · doi:10.4161/cl.24975 · Cited by 17
“IL-23 is upregulated in multiple human cancers and ablation of the Il23p19 gene resulted in reduced tumorigenesis in a mouse model of skin cancer.(33) In colonic adenomas, IL-23 signals to hematopoietic cells and upregulates the expression of other cytokines including IL-6, IL-17, and IL-22.”
BackgroundBakker, D., Bakker, W. J., Bekkenk, M. W., & Luiten, R. M. (2023) · Cells · doi:10.3390/cells12202441 · Cited by 16
“Th17 cells also secrete IL-23, which promotes chronic inflammation within the TME, which, in turn, results in increased tumorigenesis in the DMBA/TPA chemical murine skin carcinogenesis model [53].”
BackgroundIL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events
Gu, S. L., Maier, T., Moy, A. P., Dusza, S. W., Faleck, D. M., Shah, N. J., & Lacouture, M. E. (2023) · Pharmaceuticals · doi:10.3390/ph16111548 · Cited by 15
“IL23 appears to have the opposite effect and has been shown to increase carcinogenesis and tumor activity in animal systems exposed to exogenous IL-23 [36–38].”
BackgroundLiu, S., Rivero, S. L., Zhang, B., Shen, K., Li, Z., Niu, T., Rowan, B. G., Jazwinski, S. M., Abdel‐Mageed, A. B., Steele, C. H., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae120 · Cited by 16
“As IL-23 is an angiogenic factor (24), we assessed angiogenesis in mouse prostate tumors using immunohistochemical staining of CD31.”
MethodWu, J., Lv, X., Zhu, S., Li, T., Cheng, H., & Chen, J. (2019) · Journal of Immunology Research · doi:10.1155/2019/1325181 · Cited by 17
“Increased IL-23 expression levels in human colon tumors have been observed, which were associated with tumor progression and worse prognosis [109, 110].”
BackgroundEl‐Gedamy, M. S., El-Khayat, Z., Abol‐Enein, H., Elsaid, A. M. M., & El-Nahrery, E. M. A. (2021) · Immunogenetics · doi:10.1007/s00251-021-01205-w · Cited by 15
Virus Infection, Inflammation and Prevention of Cancer
Woller, N., & Kühnel, F. (2013) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-38965-8_3 · Cited by 16
Jinushi, M., Yagita∥, H., Yoshiyama, H., & Tahara, H. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.06.001 · Cited by 17
Xu, L., Wang, C., Wen, Z., Zhou, Y., Liu, Z., Liang, Y., Xu, Z., & Ren, T. (2010) · Journal of Immunology Research · doi:10.1155/2010/410893 · Cited by 15
“Some research works reported that IL-17A, IL-23, and IL-6 could promote tumor growth and/or impair the function of effector T cells, suggesting that Th17 cells might play a negative role in antitumor immunity [21–23], while others”
BackgroundInteraction of Immune and Cancer Cells
Klink, M. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1300-4 · Cited by 18
The Dark Side of the Force: When the Immune System Is the Fuel of Tumor Onset
Digifico, E., Balinzo, S., & Belgiovine, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031224 · Cited by 15
Cancer microenvironment and genomics: evolution in process
Leong, S. P. L., Witz, I. P., Sagi‐Assif, O., Izraely, S., Sleeman, J. P., Piening, B., Fox, B. A., Bifulco, C. B., Martini, R. N., Newman, L. A., et al. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10097-9 · Cited by 17
“This protease inhibitor may either promote or confine tumor progression [18, 19]; IL-23 [20], a cytokine known to support growth of several types of tumors [21]; GM-CSF [22], a constituent of various anticancer immunotherapy trials [23]; Aldolase C (Izraely et al.”
BackgroundImmunoregulation effects of TIM-3 on tumors
Sheng, C. C., & Han, F. (2018) · Neoplasma · doi:10.4149/neo_2018_180610n385 · Cited by 17
Inflame and restrain — the paradoxical roles of IL-12 and IL-23 in immunity
Rindlisbacher, L., Navarro, M. N., & Becher, B. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-025-01255-1 · Cited by 19
“Increased IL-23 serum levels were also found across various human cancers and generally correlated with poor survival, particularly in patients with breast cancer 102–104 .”
Margiotta, F. M., Michelucci, A., Fidanzi, C., Granieri, G., Salvia, G., Bevilacqua, M., Janowska, A., Dini, V., & Romanelli, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144089 · Cited by 14
“The blockade of IL-23p40 affects the modulation of wound healing by upregulating MMP-9, which is known to have a downstream role in angiogenesis [103].”
BackgroundInterleukin-17A is involved in enhancement of tumor progression in murine intestine
Oshiro, K., Kohama, H., Umemura, M., Uyttenhove, C., Inagaki‐Ohara, K., Arakawa, T., Harada, M., Nakae, S., Iwakura, Y., Nishimaki, T., et al. (2011) · Immunobiology · doi:10.1016/j.imbio.2011.08.002 · Cited by 15
Role of lymphocytes, macrophages and immune receptors in suppression of tumor immunity
Singh, A., Anang, V., Kumari, K., Kottarath, S. K., & Verma, C. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.10.002 · Cited by 15
The role of cytokines in the pathogenesis of malignant neoplasms
Львовна, Р. В., Adamova, G. V., & Oslina, D. S. (2023) · Сибирский научный медицинский журнал · doi:10.18699/ssmj20230202 · Cited by 14
Cytokine therapy for combating animal and human diseases – A review
Dhama, K., Chakraborty, S., Wani, M. Y., Tiwari, R., & Barathidasan, R. (2013) · Research opinions in animal & veterinary sciences · Cited by 14
Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?
Stagg, J., André, F., & Loi, S. (2012) · Breast Care · doi:10.1159/000342166 · Cited by 15
Functional IL-23R rs10889677 Genetic Polymorphism and Risk of Multiple Solid Tumors: a Meta-Analysis
Zhou, S., Ruan, Y.-Q., Yu, H., Chen, Y., Yao, Y., Ma, Y., & Gao, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080627 · Cited by 16
“IL-23R could lessen immunosurveillance by CD8+ T cells and accelerate tumor proliferation as well [4].”
BackgroundInterleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?
ARGOLLO, M. C., Allocca, M., Furfaro, F., Peyrin‐Biroulet, L., & Danese, S. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190313140811 · Cited by 16
Krajewski, W. R., Karabon, L., Partyka, A., Tomkiewicz, A., Poletajew, S., Tukiendorf, A., Kołodziej, A., & Zdrojowy, R. (2020) · Central European Journal of Immunology · doi:10.5114/ceji.2020.94674 · Cited by 15
“It was reported that IL-23R could also decrease immunosurveillance by CD8+ T cells and promote tumor growth [36].”
BackgroundThe inflammatory cytokine interleukin-23 is elevated in lung cancer, particularly small cell type
Cam, C., Karagöz, B., Müftüoğlu, T., Bigi, O., Emi̇rzeoglu, L., Çelik, S., Özgün, A., Tunçel, T., & Top, C. (2016) · Współczesna Onkologia · doi:10.5114/wo.2016.61562 · Cited by 14
“Interleukin 23 is also elevated in the tumor microenvironment [21, 22] and is associated with poor prognosis [23].”
BackgroundLi, Y. J., Msaouel, P., Campbell, M. T., Hwu, P., Diab, A. K., & Kim, S. T. (2024) · RMD Open · doi:10.1136/rmdopen-2024-004308 · Cited by 13
“14 In contrast, IL-17 assumes an anti-tumorigenic role by prompting cancer cells to secrete CC-chemokine ligand 20, which recruits CC-receptor six expressing dendritic cells (DCs) into the tumour sites.”
BackgroundGuimarães, A. G. D. P., da Costa, A. G., Martins‐Filho, O. A., Pimentel, J. P. D., Zauli, D. A. G., Peruhype-Magalhães, V., Teixeira‐Carvalho, A., Béla, S. R., Pascoal-Xavier, M. A., Coelho-dos-Reis, J. G. A., et al. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000412 · Cited by 13
Type 1 and 2 T helper cell-mediated colitis
Dohi, T., & Fujihashi, K. (2006) · Current Opinion in Gastroenterology · doi:10.1097/01.mog.0000245545.80160.0f · Cited by 13
Novel biologic therapies in development targeting IL‐12/IL‐23
Kerkhof, P. V. D. (2010) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2010.03830.x · Cited by 13
Innate lymphoid cells and cancer at border surfaces with the environment
Mattiola, I., & Diefenbach, A. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.06.001 · Cited by 13
Adamo, V., Franchina, T., Minciullo, P. L., Pace, E., Colonese, F., Ricciardi, G. R. R., Saitta, S., Ferraro, M., Spatari, G., & Gangemi, S. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22653 · Cited by 13
“Genetic deletion or antibody-mediated elimination of IL-23 leads to increased infiltration of cytotoxic T cells into the transformed tissue, rendering a protective effect against chemically induced carcinogenesis (Langowski et al., 2006).”
BackgroundInfluentialEndoscopic healing should be a goal for everyone with ulcerative colitis
Kane, S. V. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20779 · Cited by 13
Wang, L., Lin, J., Zhou, Z., Huo, R., Shen, B., Sun, Y., & Li, N. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027289 · Cited by 13
Khan, T., Heffron, C. L., High, K. P., & Roberts, P. C. (2014) · Virology Journal · doi:10.1186/1743-422x-11-78 · Cited by 13
“It should be noted that soluble IL-23 has been reported to have adverse effects such as inducing chronic inflammation and autoimmune disease [34,35] and both antitumor and tumor promoting effects [36,37].”
BackgroundThe dichotomy of T helper 17 cells in cancer
Dahal, L. N. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.93 · Cited by 14
Treatment of psoriasis vulgaris with guselkumab in a patient with non-small cell lung cancer
Kamiya, K., Yamauchi, H., & Ohtsuki, M. (2020) · European Journal of Dermatology · doi:10.1684/ejd.2020.3860 · Cited by 13
“IL-23 is thought to promote tumour development [5], and IL-23 induces innate inflammatory infiltration but dramatically down-regulates the ability of CD8 T cells to infiltrate tumours [5].”
BackgroundInnate lymphoid cells in early tumor development
Warner, K., Ghaedi, M., Chung, D. C., Jacquelot, N., & Ohashi, P. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.948358 · Cited by 14
“Conflicting roles were described for IL-23 in the development of chemically-induced cutaneous tumors, as tumor growth was either inhibited (112) or enhanced (138) in p19-deficient mice, depending on the background strain.”
BackgroundAssociation of interleukin-23 receptor gene polymorphisms with risk of bladder cancer in Chinese
Tang, T., Xue, H., Cui, S., Gong, Z., Fei, Z., Cheng, S., & Gui, C. (2014) · Familial Cancer · doi:10.1007/s10689-014-9731-6 · Cited by 13
RORγT agonists as immune modulators in anticancer therapy.
Pastwińska, J., Karwaciak, I., Karaś, K., Bachorz, R. A., & Ratajewski, M. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189021 · Cited by 16
Huo, M., Adeerjiang, Y., Abulitipu, A., Khan, U., Li, X.-X., Zhang, L., Tian, Y., Jiang, S., Xu, C., Chao, X.-Z., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1325575 · Cited by 12
Supersulfide donors and their therapeutic targets in inflammatory diseases
Zhang, T., Pan, Y., Sawa, T., Akaike, T., & Matsunaga, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1581385 · Cited by 14
“T cells also exhibit dual roles in a tumor microenvironment via cytokines secretion (93).”
Th17 expression and IL-17 levels in laryngeal squamous cell carcinoma patients
Li, F., Cai, Z., Yang, F., Zhang, S., & Chen, M. (2016) · Acta Oto-Laryngologica · doi:10.3109/00016489.2015.1126857 · Cited by 12
“Previous studies have suggested that IL-23 plays a role in inflammation and tumor immunosurveillance [5], and our present data suggest that IL23 might play an important role in the tumor microenvironment in patients with laryngeal squamous cell carcinoma.”
BackgroundNeuroendocrine and Behavioral Consequences of Hyperglycemia in Cancer
Vasquez, J. H., & Borniger, J. C. (2020) · Endocrinology · doi:10.1210/endocr/bqaa047 · Cited by 14
“In tumor environments, the expression of the cytokine interleukin 23 is widely observed (40).”
BackgroundPepe, F. F., Cazzaniga, M. E., Baroni, S., Riva, F., Cicchiello, F., Capici, S., Cogliati, V., Maggioni, C., Cordani, N., Cerrito, M. G., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-10031-6 · Cited by 13
Gracia‐Cazaña, T., Monroig, J. R., Izu, R., Yanguas, I., Espés, M. L., Salas, M. P. S., García‐Gil, M. F., Navarro‐Bielsa, A., Manrique, B. A., Blasco, M. A., et al. (2024) · JAAD International · doi:10.1016/j.jdin.2024.02.019 · Cited by 12
“9 Guselkumab’s effectiveness extends to addressing the full spectrum of psoriatic manifestations, offering rapid and sustained responses with a commendable safety profile.”
BackgroundCancer research: A hurdle race
Lichtenstein, A. V. (2014) · Biochemistry (Moscow) · doi:10.1134/s0006297914050010 · Cited by 12
Reay, J. C., Gambotto, A. A., & Robbins, P. D. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2011.78 · Cited by 12
Fujiwara, S., Nagai, H., Shimoura, N., Oniki, S., Yoshimoto, T., & Nishigori, C. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.42 · Cited by 12
[Role of IL-12P40 and IL-10 in progression of colorectal cancer].
Stanilov, N., Miteva, L. D., Stankova, N., Jovchev, J. P., Deliyski, T. S., & Stanilova, S. A. (2010) · PubMed · Cited by 12
Association of IL-23R Polymorphisms (rs6682925, rs10889677, rs1884444) With Cancer Risk
Liu, X., Dai, Z.-M., Kang, H., Lin, S., Ma, X., Wang, M., Liu, K., Dai, C., Wang, X.-J., & Dai, Z.-J. (2015) · Medicine · doi:10.1097/md.0000000000002361 · Cited by 12
“Moreover, previous studies have indicated that IL-23R exerts an immunosurveillance function via CD8þ T-cells and accelerates tumor growth.(15) These findings suggest that IL-23R may play an important role in cancer development and progression.”
Polyester nanomedicines targeting inflammatory signaling pathways for cancer therapy
Das, S. S., Singh, S. K., Verma, P. R. P., Gahtori, R., Sibuh, B. Z., Kesari, K. K., Jha, N. K., Dhanasekaran, S., Thakur, V. K., Wong, L. S., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113654 · Cited by 13
Overview of genetic signaling pathway interactions within cutaneous malignancies
Maner, B. S., Dupuis, L., Su, A., Jueng, J., Harding, T. P., Meisenheimer, J. L., Siddiqui, F. S., Hardack, M. R., Aneja, S., & Solomon, J. A. (2020) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2020.60 · Cited by 16
“Deletion of IL-23 was shown to restrict tumor growth, leading to protection against carcinogenesis([118]).”
BackgroundZhu, H., & Liu, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.666340 · Cited by 12
“Further analysis elucidates that chemotherapeutics specifical ly acting on MDSCs and CSCs to reduce immunosuppression in the TME remarkably amplify efficiency and efficacy of ICI treatment and adoptive cell therapy (282, 283).”
BackgroundInfluentialCellular and Molecular Mechanisms of Tumor Promotion
Rundhaug, J. E., & Fischer, S. M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.01416-0 · Cited by 13
Targeting IL-23 for the interception of obesity-associated colorectal cancer
Madka, V., Chiliveru, S., Panneerselvam, J., Pathuri, G., Zhang, Y., Stratton, N. C., Kumar, N., Sanghera, D. K., & Rao, C. V. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100939 · Cited by 11
“Moreover, IL-23 is also shown to promote other cancers including those of the skin [12] and kidneys.”
BackgroundAudia, S., Brescia, C., Dattilo, V., Torchia, N., Trapasso, F., & Amato, R. (2024) · Cancers · doi:10.3390/cancers17010055 · Cited by 11
“As posited by Langowski et al., the IL-23/IL-23R axis represents a significant molecular conduit between tumor-promoting pro-inflammatory processes and the failure of adaptive immune surveillance to infiltrate tumors [125].”
Immuno-onco-metabolism and Therapeutic Resistance
Mir, M. A., Aisha, S., Nisar, S., Qayoom, H., & Mehraj, U. (2022) · Springer eBooks · doi:10.1007/978-981-16-6226-3_3 · Cited by 11
Metadata
- Authors
- Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M.
- Corresponding author
- Oft, Martin
- Venue
- Nature
- Published
- 2006-05-10
- Volume
- 442
- Issue
- 7101
- Pages
- 461-465
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1984467626
- Cited by
- 1,018
- References
- 30
- Citations by year
- 2026: 23 · 2025: 18 · 2024: 32 · 2023: 46 · 2022: 42 · 2021: 44 · 2020: 41 · 2019: 52 · 2018: 41 · 2017: 41 · 2016: 41 · 2015: 47 · 2014: 62 · 2013: 72 · 2012: 65
- FWCI
- 24.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- IL-23, tumour-associated inflammation, tumor surveillance, CD8+ T cell infiltration, intraepithelial lymphocytes, tumor microenvironment, angiogenesis, MMP-9, IL-12, chemical carcinogenesis, IL23R, tumor growth, cancer immunotherapy
- MeSH terms
- Animals, Cell Division, Humans, Inflammation, Interleukins, Mice, Inbred C57BL, Neoplasms, Signal Transduction, CD8-Positive T-Lymphocytes, Interleukin-12, Genetic Predisposition to Disease, Mice, Interleukin-23, Interleukin-23 Subunit p19
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.